We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Northwest Biotherapeutics

News List

Northwest Biotherapeutics Adds Production Capacity at UK Facility contractpharma
March 18, 2021
Dendritic cell vaccine production capacity for personalized immune therapies increases from about 4 - 6 patients per month to about 40 - 45 patients per month.
Northwest Biotherapeutics Acquires Flaskworks americanpharmaceuticalreview
September 03, 2020
Northwest Biotherapeutics announced the Company has acquired Flaskworks, a company that has developed a system to close and automate the manufacturing of cell therapy products such as DCVax®.
NW Bio Accelerating Sawston Plant Phase I Buildout contractpharma
September 02, 2020
Construction crews working double shifts to accelerate completion despite COVID effects.
NW Bio Announces $5 Million Bridge Funding firstwordpharma
November 14, 2018
Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers